GlassScriptPhysician profile
William Lee Forehand
NPI 1235513607
$15,039.01
in general payments reported to CMS, 2019-2025
65 companies · $4,831 in 2025
The $4,831 reported for 2025 was more than what 82% of Hematology & Oncology providers received nationally (typical 2025 total: $686).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $426 · 2021: $492 · 2022: $2,285 · 2023: $2,238 · 2024: $4,767 · 2025: $4,831.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $9,518 · Long Term Medical Supply Or Device Loan: $2,180 · Education: $138.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $9,517.91 |
| Long Term Medical Supply Or Device Loan | $2,179.99 |
| Education | $137.66 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $3,010.60 | 2022-2025 | Kisqali, Piqray |
| Astrazeneca Pharmaceuticals LP | $852.90 | 2019-2025 | Tagrisso, Enhertu, Lynparza |
| Pfizer INC. | $788.60 | 2021-2025 | |
| Secura Bio, INC. | $764.93 | 2022-2025 | Copiktra |
| Merck Sharp & Dohme LLC | $669.90 | 2023-2025 | Keytruda, Lynparza, Welireg |
| Daiichi Sankyo INC. | $617.13 | 2022-2025 | Enhertu, Injectafer, Vanflyta |
| Seagen INC. | $498.89 | 2021-2023 | Adcetris, Tukysa, Padcev |
| Genentech USA, INC. | $496.43 | 2019-2025 | Polivy, Lunsumio, Tecentriq |
| Janssen Biotech, INC. | $483.32 | 2022-2025 | Darzalex, Erleada, Imbruvica |
| Incyte Corporation | $398.78 | 2019-2025 | Jakafi, Monjuvi, Zynyz |
| E.R. Squibb & Sons, L.L.C. | $386.68 | 2022-2025 | Opdivo, Opdualag |
| Eisai INC. | $380.96 | 2022-2025 | |
| Abbvie INC. | $367.66 | 2023-2025 | |
| Genzyme Corporation | $329.63 | 2022-2025 | |
| Regeneron Healthcare Solutions, INC. | $320.16 | 2021-2025 | Libtayo |
Show all 65 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Glaxosmithkline, LLC. | $309.93 | 2021-2025 | Ojjaara, Blenrep, Shingrix |
| Bayer Healthcare Pharmaceuticals INC. | $295.87 | 2022-2025 | |
| Takeda Pharmaceuticals U.S.A., INC. | $267.88 | 2022-2025 | Alunbrig, Iclusig, Ninlaro |
| Amgen INC. | $255.07 | 2021-2022 | |
| Rigel Pharmaceuticals, INC. | $225.44 | 2023-2025 | Rezlidhia, Tavalisse, Tavalisse |
| Jazz Pharmaceuticals INC. | $211.20 | 2022-2025 | |
| Celgene Corporation | $202.70 | 2022-2024 | Pomalyst, Reblozyl |
| Gilead Sciences, INC. | $200.77 | 2022-2025 | Trodelvy |
| Sobi, INC | $167.66 | 2022-2025 | |
| Legend Biotech USA INC. | $162.92 | 2024-2025 | Carvykti |
| Array Biopharma INC | $139.46 | 2022-2025 | Braftovi, Mektovi, Tukysa |
| Deciphera Pharmaceuticals INC. | $139.12 | 2021-2025 | Qinlock, Romvimza, Tgct |
| Exelixis INC. | $138.62 | 2023-2024 | Cabometyx |
| Foundation Medicine, INC. | $136.89 | 2021-2023 | |
| Puma Biotechnology, INC. | $127.49 | 2022-2025 | |
| Ipsen Biopharmaceuticals, INC | $115.18 | 2019 | |
| Astellas Pharma US INC | $94.63 | 2024-2025 | Xtandi, Vyloy, Padcev |
| Beone Medicines USA, INC. | $89.02 | 2025 | Brukinsa |
| Karyopharm Therapeutics INC. | $83.66 | 2022-2025 | Xpovio |
| Stemline Therapeutics INC. | $83.45 | 2024-2025 | Orserdu |
| Pharmacyclics LLC, An Abbvie Company | $78.80 | 2022-2023 | Imbruvica |
| Springworks Therapeutics, INC. | $77.93 | 2024-2025 | Ogsiveo, Gomekli |
| Blueprint Medicines Corporation | $74.34 | 2022-2024 | Ayvakit |
| Lilly USA, LLC | $74.02 | 2023-2024 | Verzenio, Jaypirca, Retevmo |
| Beigene USA, INC. | $65.32 | 2023-2025 | Brukinsa, Tevimbra |
| Emd Serono, INC. | $63.90 | 2024-2025 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $63.71 | 2023 | Gilotrif |
| Adc Therapeutics America, INC. | $62.01 | 2022-2024 | |
| Coherus Oncology, INC. | $61.58 | 2022-2023 | |
| Agios Pharmaceuticals, INC. | $61.21 | 2024-2025 | Pyrukynd |
| Pharmaessentia USA Corporation | $56.18 | 2024-2025 | Besremi |
| Alexion Pharmaceuticals, INC. | $45.52 | 2022-2025 | Ultomiris |
| Epizyme, INC. | $37.49 | 2022 | |
| Pharmacosmos Therapeutics INC. | $36.52 | 2024-2025 | Cosela, Monoferric |
| G1 Therapeutics, INC. | $36.14 | 2023 | Cosela |
| Taiho Oncology, INC. | $34.71 | 2025 | |
| Janssen Pharmaceuticals, INC | $32.54 | 2023 | Xarelto |
| Adaptive Biotechnologies Corporation | $31.06 | 2024-2025 | Clonoseq |
| Tersera Therapeutics LLC | $27.87 | 2024 | Zoladex |
| Nuvation Bio INC. | $25.67 | 2025 | Ibtrozi |
| Avyxa Pharma, LLC | $24.19 | 2025 | |
| Sumitomo Pharma America, INC. | $23.28 | 2025 | Orgovyx |
| Tempus Ai, INC | $20.89 | 2025 | Xt Cdx |
| Aveo Pharmaceuticals, INC. | $18.84 | 2024 | |
| Servier Pharmaceuticals LLC | $17.83 | 2025 | |
| Mylan Institutional INC. | $16.47 | 2022 | |
| Mirati Therapeutics, INC. | $15.15 | 2023 | Krazati |
| Kite Pharma, INC. | $14.63 | 2022 | |
| Biomarin Pharmaceutical INC. | $13.97 | 2023 | Roctavian |
| Cti Biopharma Corp. | $13.71 | 2023 | Vonjo |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw William Forehand listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.